Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

• Main Authors: Nadia Terranova (Author), Jonathan French (Author), Haiqing Dai (Author), Matthew Wiens (Author), Akash Khandelwal (Author), Ana Ruiz‐Garcia (Author), Juliane Manitz (Author), Anja vonHeydebreck (Author), Mary Ruisi (Author), Kevin Chin (Author), Pascal Girard (Author), Karthik Venkatakrishnan (Author)
• Format: Book
• Published: Wiley, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Avelumab (anti-PD‐L1) is an approved anticancer treatment for several indications. The JAVELIN Gastric 100 phase III trial did not meet its primary objective of demonstrating superior overall survival (OS) with avelumab maintenance versus continued chemotherapy in patients with advanced gas...